CSF2 and neoplasm: A combination of ascites-derived exosomes with granulocyte-macrophage colony-stimulating factor (GM-CSF) was tested in a phase I clinical trial for the treatment of advanced colorectal cancer, which was found to be feasible and safe and also capable of eliciting more CTL infiltration in tumor regions (Dai et al., 2008).